Verona Pharma has launched two Phase 3 trials to assess the safety and effectiveness of ensifentrine, its investigational inhalation treatment for chronic obstructive pulmonary disease (COPD). The trials — called ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) — are each expected to enroll up to 800 patients…
Chronic obstructive pulmonary disease (COPD) is more prevalent than previously thought and associated with a mortality rate that is likely higher than earlier estimates, a review study has found. Invasive aspergillosis — a respiratory infection caused by molds belonging to the Aspergillus genus — may be a…
PAO Group and Puration have entered a new agreement that will allow PAO Group to build a proprietary hemp cultivar development facility on Puration’s branded site in Farmersville, Texas, according to a press release. The new facility is expected to help provide materials to further the development of…
Nebulized ensifentrine (RPL554) — which works both to widen the airways and as an anti-inflammatory — showed a significant early effect on breathlessness in people with chronic obstructive pulmonary disease (COPD), according to the therapy’s developer, Verona Pharma. Apart from easing breathlessness, in four weeks of treatment…
Synairgen‘s anti-viral therapy SNG001 has a good safety profile in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show. The data also indicate that SNG001 induces its intended anti-viral effect, and that it improves lung function in COPD patients with viral lung infections. “These…
Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) outperformed Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe exacerbations in people with chronic obstructive pulmonary disease (COPD) during all seasons of the year, new data from the ETHOS clinical trial show. That data will be presented by…
Regular, low-dose oral morphine led to significant health improvements in adults with advanced chronic obstructive pulmonary disease (COPD) who regularly experienced shortness of breath, according to results of a Phase 4 clinical trial. Treatment with morphine did not cause lung-related…
Men with moderate-to-severe chronic obstructive pulmonary disease (COPD) who drank a beverage composed of whey protein fortified with magnesium and vitamin C had lower levels of the inflammation-associated protein interleukin-6 in their blood, compared to those who did not receive the beverage,…
A blood test to measure levels of the immune signaling protein interleukin-32 (IL-32) may be a useful biomarker to diagnose and assess the severity of chronic obstructive pulmonary disease (COPD), a new study suggests. The study, “…
Evidence of a new potential therapeutic target — a protein called free fatty acid receptor 4 (FFA4) — in the treatment of inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) has been found in a new study. The study, “Pathophysiological…
Get regular updates to your inbox.